EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors

C Mircea S Tesileanu iD, Sotirios Michaleas, Rocio Gonzalo Ruiz, Segundo Mariz, Babs O Fabriek, Paula B van Hennik, Jutta Dedorath, Bruna Dekic, Christoph Unkrig, Andreas Brandt, Janet Koenig, Harald Enzmann und 2 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad119 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Oncologist, 2023. Verfasst von C Mircea S Tesileanu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asciminib is an allosteric high-affinity tyrosine kinase inhibitor (TKI) of the BCR-ABL1 protein kinase. This kinase is translated from the Philadelphia chromosome in chronic myeloid leukemia (CML). Marketing authorization for asciminib was granted on August 25, 2022 by the European Commission. The approved indication was for patients with Philadelphia chromosome-positive CML in the chronic phase which have previously been treated with at least 2 TKIs. Clinical efficacy and safety of asciminib were evaluated in the open-label, randomized, phase III ASCEMBL study. The primary endpoint of this trial was major molecular response (MMR) rate at 24 weeks. A significant difference in MRR rate was shown between the asciminib treated population and the bosutinib control group (25.5% vs. 13.2%, respectively, P = .029). In the asciminib cohort, adverse reactions of at least grade 3 with an incidence ≥ 5% were thrombocytopenia, neutropenia, increased pancreatic enzymes, hypertension, and anemia. The aim of this article is to summarize the scientific review of the application which led to the positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdultHumansDrug Resistance, NeoplasmFusion Proteins, bcr-ablPhiladelphia ChromosomeProtein Kinase InhibitorsTyrosine Kinase InhibitorsNiacinamidePyrazoles

Stichwörter der Autor:innen

BCR-ABL1EMAasciminibchronic myeloid leukemiatyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsFusion Proteins, bcr-ablProtein Kinase InhibitorsTyrosine Kinase InhibitorsasciminibNiacinamidePyrazoles

Autor:innen und Institutionen

  • Oncology and Hematology Office, European Medicines Agency, Amsterdam, The Netherlands.
  • Department of Neurology, The Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Orphan Medicines Office, European Medicines Agency, Amsterdam, The Netherlands.
  • Medicines Evaluation Board, Utrecht, The Netherlands.
  • Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency, Amsterdam, The Netherlands.
  • Federal Institute for Drugs and Medical Devices, Bonn, Germany.

ORCID-Profile: C Mircea S Tesileanu, Julio Delgado

Zitieren

APA

Tesileanu, C. M. S., Michaleas, S., Gonzalo Ruiz, R., Mariz, S., Fabriek, B. O., van Hennik, P. B., Dedorath, J., Dekic, B., Unkrig, C., Brandt, A., Koenig, J., Enzmann, H., Delgado, J., & Pignatti, F. (2023). The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors. The Oncologist. https://doi.org/10.1093/oncolo/oyad119

Vancouver

Tesileanu CMS, Michaleas S, Gonzalo Ruiz R, Mariz S, Fabriek BO, van Hennik PB, et al. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors. The Oncologist. 2023. doi:10.1093/oncolo/oyad119

BibTeX
@article{Tesileanu2023,
  author = {Tesileanu, C Mircea S and Michaleas, Sotirios and Gonzalo Ruiz, Rocio and Mariz, Segundo and Fabriek, Babs O and van Hennik, Paula B and Dedorath, Jutta and Dekic, Bruna and Unkrig, Christoph and Brandt, Andreas and Koenig, Janet and Enzmann, Harald and Delgado, Julio and Pignatti, Francesco},
  title = {The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad119}
}
Kostenlos starten →